Brian G Weinshenker

List of Publications by Year
in descending order

226 papers	49,592 citations	6233 80 h-index	1705 213 g-index
230 all docs	230 docs citations	230 times ranked	23227 citing authors

#	Article	IF	Citations
1	Multiple sclerosis diagnosis: Knowledge gaps and opportunities for educational intervention in neurologists in the United States. Multiple Sclerosis Journal, 2022, 28, 1248-1256.	1.4	12
2	AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2022, 57, 103356.	0.9	16
3	Cerebrospinal fluid evaluation in patients with progressive motor impairment due to critical central nervous system demyelinating lesions. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732110521.	0.5	1
4	Confirming a Historical Diagnosis of Multiple Sclerosis. Neurology: Clinical Practice, 2022, 12, 263-269.	0.8	4
5	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. Multiple Sclerosis Journal, 2022, 28, 1424-1456.	1.4	16
6	Neuromotor control associates with muscle weakness observed with <scp>McArdle</scp> sign of multiple sclerosis. Annals of Clinical and Translational Neurology, 2022, , .	1.7	2
7	CSF Kappa Free Light Chains: Cutoff Validation for Diagnosing Multiple Sclerosis. Mayo Clinic Proceedings, 2022, 97, 738-751.	1.4	17
8	Frequency of Asymptomatic Optic Nerve Enhancement in a Large Retrospective Cohort of Patients With Aquaporin-4+ NMOSD. Neurology, 2022, 99, .	1.5	12
9	Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar. Multiple Sclerosis and Related Disorders, 2022, 66, 104025.	0.9	15
10	Letter to the Editor Regarding â€œNetwork Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 ImmunoglobulinÂG-positive Neuromyelitis Optica Spectrum Disorderâ€• Neurology and Therapy, 2022, 11, 1439-1443.	1.4	4
11	MOG-IgG1 and co-existence of neuronal autoantibodies. Multiple Sclerosis Journal, 2021, 27, 1175-1186.	1.4	29
12	Challenges in multiple sclerosis diagnosis: Misunderstanding and misapplication of the McDonald criteria. Multiple Sclerosis Journal, 2021, 27, 250-258.	1.4	32
13	Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies. Multiple Sclerosis Journal, 2021, 27, 303-308.	1.4	64
14	Critical spinal cord lesions associate with secondary progressive motor impairment in long-standing MS: A population-based case-control study. Multiple Sclerosis Journal, 2021, 27, 667-673.	1.4	7
15	Coexisting systemic and organ-specific autoimmunity in MOG-IgG1-associated disorders versus AQP4-IgG+ NMOSD. Multiple Sclerosis Journal, 2021, 27, 630-635.	1.4	25
16	Onset of progressive motor impairment in patients with critical central nervous system demyelinating lesions. Multiple Sclerosis Journal, 2021, 27, 895-902.	1.4	4
17	Inflammatory activity following motor progression due to critical CNS demyelinating lesions. Multiple Sclerosis Journal, 2021, 27, 1037-1045.	1.4	3
18	Utility of MRI Enhancement Pattern in Myelopathies With Longitudinally Extensive T2 Lesions. Neurology: Clinical Practice, 2021, 11, e601-e611.	0.8	21

#	Article	IF	Citations
19	Spinal Cord Compression and Myelopathies. , 2021, , 251-278.		0
20	Biomechanical muscle stiffness measures of extensor digitorum explain potential mechanism of McArdle sign. Clinical Biomechanics, 2021, 82, 105277.	0.5	2
21	Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD. Multiple Sclerosis Journal, 2021, 27, 2052-2061.	1.4	11
22	Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	20
23	Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker. Annals of Neurology, 2021, 89, 895-910.	2.8	72
24	Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective. JAMA Neurology, 2021, 78, 351.	4.5	30
25	Vessel Wall Enhancement in Unilateral Primary Angiitis of the Central Nervous System. Canadian Journal of Neurological Sciences, 2021, , 1-3.	0.3	0
26	Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing. JAMA Neurology, 2021, 78, 741.	4.5	124
27	Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders. Neurology, 2021, 97, e1097-e1109.	1.5	77
28	CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies. Neurology, 2021, 97, e1351-e1358.	1.5	25
29	Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurology, The, 2021, 20, 762-772.	4.9	261
30	Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 384-390.	0.9	55
31	Hope for patients with neuromyelitis optica spectrum disorders â€" from mechanisms to trials. Nature Reviews Neurology, 2021, 17, 759-773.	4.9	57
32	Clinical Significance of Myelin Oligodendrocyte Glycoprotein Autoantibodies in Patients with Typical MS Lesions on MRI. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110487.	0.5	5
33	Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110526.	0.5	11
34	The frequency of longitudinally extensive transverse myelitis in MS: A population-based study. Multiple Sclerosis and Related Disorders, 2020, 37, 101487.	0.9	35
35	Does area postrema syndrome occur in myelin oligodendrocyte glycoprotein-IgGâ€"associated disorders (MOGAD)?. Neurology, 2020, 94, 85-88.	1.5	30
36	Neuromyelitis optica. Nature Reviews Disease Primers, 2020, 6, 85.	18.1	232

#	Article	IF	Citations
37	Application of 2015 Seronegative Neuromyelitis Optica Spectrum Disorder Diagnostic Criteria for Patients With Myelin Oligodendrocyte Glycoprotein IgGâ€“Associated Disorders. JAMA Neurology, 2020, 77, 1572.	4.5	14
38	Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	112
39	Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events. JAMA Neurology, 2020, 77, 937.	4.5	78
40	Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. Multiple Sclerosis and Related Disorders, 2020, 44, 102251.	0.9	110
41	Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	29
42	Radiologically Isolated Syndrome: <scp>10â€Year</scp> Risk Estimate of a Clinical Event. Annals of Neurology, 2020, 88, 407-417.	2.8	95
43	Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology, 2020, 95, e111-e120.	1.5	140
44	Efficacy and Safety of Satralizumab for Relapse Prevention in Neuromyelitis Optica Spectrum Disorder: A Pooled Analysis from Two Phase 3 Clinical Trials. Multiple Sclerosis and Related Disorders, 2020, 37, 101592.	0.9	1
45	Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. Frontiers in Neurology, 2020, 11, 501.	1.1	216
46	Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurology, The, 2020, 19, 402-412.	4.9	278
47	Reproductive history and progressive multiple sclerosis risk in women. Brain Communications, 2020, 2, fcaa185.	1.5	28
48	Glial fibrillary acidic protein IgG related myelitis: characterisation and comparison with aquaporin-4-IgG myelitis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 488-490.	0.9	54
49	Testing for Myelin Oligodendrocyte Glycoprotein Antibody (MOG-IgG) in typical MS. Multiple Sclerosis and Related Disorders, 2019, 35, 34-35.	0.9	2
50	McArdle Sign: A Specific Sign of Multiple Sclerosis. Mayo Clinic Proceedings, 2019, 94, 1427-1435.	1.4	7
51	Aquaporin-4 and MOG autoantibody discovery in idiopathic transverse myelitis epidemiology. Neurology, 2019, 93, e414-e420.	1.5	26
52	Long-term outcome and prognosis in patients with neuromyelitis optica spectrum disorder from Serbia. Multiple Sclerosis and Related Disorders, 2019, 36, 101413.	0.9	14
53	Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet, The, 2019, 394, 1352-1363.	6.3	433
54	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. Lancet Neurology, The, 2019, 18, 185-197.	4.9	110

#	Article	IF	Citations
55	Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. Brain, 2019, 142, 1858-1875.	3.7	303
56	Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders. Brain, 2019, 142, 1310-1323.	3.7	131
57	Unilateral motor progression in MS. Neurology, 2019, 93, e628-e634.	1.5	22
58	Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody. JAMA Neurology, 2019, 76, 301.	4.5	243
59	Characteristics of Spontaneous Spinal Cord Infarction and Proposed Diagnostic Criteria. JAMA Neurology, 2019, 76, 56.	4.5	134
60	Demographics and clinical characteristics of episodic hypothermia in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 709-714.	1.4	4
61	Comment on 2018 American Academy of Neurology guidelines on disease-modifying therapies in MS. Neurology, 2018, 90, 1106-1112.	1.5	15
62	Cervical spinal cord atrophy. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e435.	3.1	57
63	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurology, The, 2018, 17, 162-173.	4.9	4,605
64	Novel Glial Targets and Recurrent Longitudinally Extensive Transverse Myelitis. JAMA Neurology, 2018, 75, 892.	4.5	17
65	Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis. Ophthalmology, 2018, 125, 1628-1637.	2.5	108
66	Spinal cord infarction: Clinical and imaging insights from the periprocedural setting. Journal of the Neurological Sciences, 2018, 388, 162-167.	0.3	28
67	Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: A predominantly population-based study. Multiple Sclerosis Journal, 2018, 24, 331-339.	1.4	45
68	Optic Disc Edema in Glial Fibrillary Acidic Protein Autoantibodyâ€“Positive Meningoencephalitis. Journal of Neuro-Ophthalmology, 2018, 38, 276-281.	0.4	36
69	Area postrema syndrome. Neurology, 2018, 91, e1642-e1651.	1.5	129
70	Population-based study of â€œno evident disease activityâ€•in MS. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e495.	3.1	6
71	Myelin Oligodendrocyte Glycoprotein Antibodyâ€“Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. American Journal of Ophthalmology, 2018, 195, 8-15.	1.7	295
72	Progressive motor impairment from a critically located lesion in highly restricted CNS-demyelinating disease. Multiple Sclerosis Journal, 2018, 24, 1445-1452.	1.4	18

#	Article	IF	Citations
73	Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgGâ€"Associated Disorders. JAMA Neurology, 2018, 75, 1355.	4.5	286
74	â€œA rose by any other nameâ€: does defining extreme phenotypes add to the management of multiple sclerosis?. Annals of Translational Medicine, 2018, 6, 396-396.	0.7	1
75	Glial fibrillary acidic protein immunoglobulin <scp>G</scp> as biomarker of autoimmune astrocytopathy: Analysis of 102 patients. Annals of Neurology, 2017, 81, 298-309.	2.8	366
76	Variation in MS outcome. Neurology, 2017, 88, 1214-1215.	1.5	0
77	Neuromyelitis optica spectrum disorder diagnostic criteria: Sensitivity and specificity are both important. Multiple Sclerosis Journal, 2017, 23, 182-184.	1.4	12
78	Ring-enhancing spinal cord lesions in neuromyelitis optica spectrum disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 218-225.	0.9	53
79	Myelitis in neuromyelitis optica spectrum disorder: The long and the short of it. Multiple Sclerosis Journal, 2017, 23, 360-361.	1.4	6
80	Elsberg syndrome. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e355.	3.1	55
81	BalÃ³ concentric sclerosis evolving from apparent tumefactive demyelination. Neurology, 2017, 88, 2150-2152.	1.5	16
82	Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e343.	3.1	55
83	Author response: The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study. Neurology, 2017, 88, 2067-2068.	1.5	0
84	Neuromyelitis Spectrum Disorders. Mayo Clinic Proceedings, 2017, 92, 663-679.	1.4	224
85	Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter study. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e339.	3.1	32
86	High risk of postpartum relapses in neuromyelitis optica spectrum disorder. Neurology, 2017, 89, 2238-2244.	1.5	59
87	Neuromyelitis optica spectrum disorders and pregnancy: Interactions and management. Multiple Sclerosis Journal, 2017, 23, 1808-1817.	1.4	35
88	Disease-modifying therapies can be safely discontinued in an individual with stable relapsing-remitting MS â€" NO. Multiple Sclerosis Journal, 2017, 23, 1190-1192.	1.4	9
89	Atypical inflammatory demyelinating syndromes of the CNS. Lancet Neurology, The, 2016, 15, 967-981.	4.9	121
90	What <scp>I</scp>s the <scp>O</scp>ptimal <scp>S</scp>equence of <scp>R</scp>escue <scp>T</scp>reatments for <scp>A</scp>ttacks of <scp>N</scp>euromyelitis <scp>O</scp>ptica <scp>S</scp>pectrum <scp>D</scp>isorder?. Annals of Neurology, 2016, 79, 204-205.	2.8	7

#	Article	IF	Citations
91	Epidemiology of aquaporinâ€4 autoimmunity and neuromyelitis optica spectrum. Annals of Neurology, 2016, 79, 775-783.	2.8	263
92	Pediatric familial neuromyelitis optica in two sisters with long term follow-up. Journal of Clinical Neuroscience, 2016, 29, 183-184.	0.8	8
93	Does early (treatment in) BENEFIT lead to late MS benefit?. Neurology, 2016, 87, 970-971.	1.5	0
94	The contemporary spectrum of multiple sclerosis misdiagnosis. Neurology, 2016, 87, 1393-1399.	1.5	230
95	Disease modifying therapies for relapsing multiple sclerosis. BMJ, The, 2016, 354, i3518.	3.0	127
96	Central canal enhancement and the trident sign in spinal cord sarcoidosis. Neurology, 2016, 87, 743-744.	1.5	94
97	Progressive solitary sclerosis. Neurology, 2016, 87, 1713-1719.	1.5	59
98	Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. Scientific Reports, 2016, 6, 28484.	1.6	660
99	Discriminating long myelitis of neuromyelitis optica from sarcoidosis. Annals of Neurology, 2016, 79, 437-447.	2.8	148
100	Placebo-controlled study in neuromyelitis opticaâ€"Ethical and design considerations. Multiple Sclerosis Journal, 2016, 22, 862-872.	1.4	63
101	International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology, 2016, 86, 491-492.	1.5	68
102	Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. Journal of Neurology, 2016, 263, 140-149.	1.8	60
103	Short Myelitis Lesions in Aquaporin-4-IgGâ€"Positive Neuromyelitis Optica Spectrum Disorders. JAMA Neurology, 2015, 72, 81.	4.5	209
104	Placebo Studies should not be Undertaken in Neuromyelitis Optica: Commentary. Multiple Sclerosis Journal, 2015, 21, 693-694.	1.4	3
105	Moving Targets for Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. JAMA Neurology, 2015, 72, 147.	4.5	1
106	Posterior reversible encephalopathy syndrome is not associated with mutations in aquaporin-4: Table. Neurology: Genetics, 2015, 1, e19.	0.9	0
107	Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis. Neurology, 2015, 85, 722-729.	1.5	86
108	A Clinical Approach to the Differential Diagnosis of Multiple Sclerosis. Current Neurology and Neuroscience Reports, 2015, 15, 57.	2.0	29

#	Article	IF	Citations
109	Corticosteroid-Induced Paraplegiaâ€"A Diagnostic Clue for Spinal Dural Arterial Venous Fistula. JAMA Neurology, 2015, 72, 833.	4.5	28
110	Teaching Neuro Images : Primary SjÃ¶gren syndrome presenting as isolated lesion of medulla oblongata. Neurology, 2015, 85, 204-205.	1.5	1
111	International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology, 2015, 85, 177-189.	1.5	3,275
112	Asymptomatic myelitis in neuromyelitis optica and autoimmune aquaporin-4 channelopathy. Neurology: Clinical Practice, 2015, 5, 175-177.	0.8	21
113	Challenges and opportunities in designing clinical trials for neuromyelitis optica. Neurology, 2015, 84, 1805-1815.	1.5	39
114	Tumefactive demyelinating lesions: Characteristics of individual lesions, individual patients, or a unique disease entity?. Multiple Sclerosis Journal, 2015, 21, 1746-1747.	1.4	10
115	EXPERT OPINIONS ON THE DIAGNOSIS AND TREATMENT OF PATIENTS WITH AQP4-NEGATIVE NMO/MS OVERLAPPING SYNDROMES. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.40-e4.	0.9	0
116	Update on biomarkers in neuromyelitis optica. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e134.	3.1	104
117	Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions. Neurology, 2015, 84, 148-158.	1.5	49
118	Relapses and disability accumulation in progressive multiple sclerosis. Neurology, 2015, 84, 81-88.	1.5	92
119	Pregnancy outcomes in a woman with neuromyelitis optica. Neurology, 2014, 83, 1576-1577.	1.5	20
120	Aquaporin 4 IgG Serostatus and Outcome in Recurrent Longitudinally Extensive Transverse Myelitis. JAMA Neurology, 2014, 71, 48.	4.5	51
121	Hydrocephalus in neuromyelitis optica. Neurology, 2014, 82, 1841-1843.	1.5	22
122	Evaluation of aquaporinâ€4 antibody assays. Clinical and Experimental Neuroimmunology, 2014, 5, 290-303.	0.5	106
123	Teaching Neuro Images : MRI in advanced neuromyelitis optica. Neurology, 2014, 82, e101-2.	1.5	6
124	Longitudinally extensive transverse myelitis. Current Opinion in Neurology, 2014, 27, 279-289.	1.8	56
125	Relapsing inappropriate antidiuretic hormone secretion in an anti-aquaporin-4 antibody positive paediatric patient. Multiple Sclerosis Journal, 2014, 20, 1404-1406.	1.4	4
126	The two faces of neuromyelitis optica. Neurology, 2014, 82, 466-467.	1.5	21

#	Article	IF	Citations
127	Active and progressive. Neurology, 2014, 83, 206-207.	1.5	7
128	Neuromyelitis Optica Spectrum Disorders. Current Neurology and Neuroscience Reports, 2014, 14, 483.	2.0	42
129	Anterior spinal artery infarction causing man-in-the-barrel syndrome. Neurology: Clinical Practice, 2014, 4, 268-269.	0.8	9
130	The investigation of acute optic neuritis: a review and proposed protocol. Nature Reviews Neurology, 2014, 10, 447-458.	4.9	248
131	Neuromyelitis optica (Devicâ€™s syndrome). Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 122, 581-599.	1.0	53
132	Clinical spectrum of neuromyelitis optica 2013. Neurology and Clinical Neuroscience, 2014, 2, 23-27.	0.2	2
133	Specific pattern of gadolinium enhancement in spondylotic myelopathy. Annals of Neurology, 2014, 76, 54-65.	2.8	89
134	Review: In relapsingâ€“remitting multiple sclerosis, disease-modifying agents reduce annual relapse rates. Annals of Internal Medicine, 2014, 160, JC5.	2.0	1
135	Aquaporin 4 Expression and Tissue Susceptibility to Neuromyelitis Optica. JAMA Neurology, 2013, 70, 1118.	4.5	70
136	Misdiagnosis of Multiple Sclerosis: Frequency, Causes, Effects, and Prevention. Current Neurology and Neuroscience Reports, 2013, 13, 403.	2.0	76
137	Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurology, The, 2013, 12, 554-562.	4.9	335
138	Intractable Nausea and Vomiting From Autoantibodies Against a Brain Water Channel. Clinical Gastroenterology and Hepatology, 2013, 11, 240-245.	2.4	49
139	Simultaneous PML-IRIS and myelitis in a patient with neuromyelitis optica spectrum disorder. Neurology: Clinical Practice, 2013, 3, 448-451.	0.8	10
140	Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology, 2013, 81, 1197-1204.	1.5	206
141	Christian Confavreux (1949 â€“ 2013). Multiple Sclerosis Journal, 2013, 19, 1811-1812.	1.4	1
142	TNFRSF1A polymorphisms and MS. Neurology, 2013, 80, 2002-2003.	1.5	0
143	Acute Disseminated Encephalomyelitis, Transverse Myelitis, and Neuromyelitis Optica. CONTINUUM Lifelong Learning in Neurology, 2013, 19, 944-967.	0.4	27
144	Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 188-198.	1.4	205

#	Article	IF	Citations
145	Teaching Neuro Images : â€œPancake-likeâ€•gadolinium enhancement suggests compressive myelopathy due to spondylosis. Neurology, 2013, 80, e229.	1.5	11
146	Pregnancy. Neurology, 2012, 78, 846-848.	1.5	7
147	Solitary sclerosis: Progressive myelopathy from solitary demyelinating lesion. Neurology, 2012, 78, 540-544.	1.5	44
148	Industrial pharmaceutical drug research has done more for the health of people with MS than academic neurologists: No. Multiple Sclerosis Journal, 2012, 18, 1211-1212.	1.4	1
149	Effects of Age and Sex on Aquaporin-4 Autoimmunity. Archives of Neurology, 2012, 69, 1039-43.	4.9	91
150	Plasmapheresis: are bigger studies necessarily better?. Nature Reviews Neurology, 2012, 8, 410-410.	4.9	1
151	Acute Demyelinating Disorders: Emergencies and Management. Neurologic Clinics, 2012, 30, 285-307.	0.8	12
152	The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Multiple Sclerosis Journal, 2012, 18, 5-10.	1.4	192
153	Spinal Cord Compression and Myelopathies. , 2012, , 235-257.		0
154	Optic neuritis in an ethnically diverse population: Higher risk of atypical cases in patients of African or African-Caribbean heritage. Journal of the Neurological Sciences, 2012, 312, 21-25.	0.3	31
155	Treatment of neuromyelitis optica: Review and recommendations. Multiple Sclerosis and Related Disorders, 2012, 1, 180-187.	0.9	217
156	Lupus Related Longitudinal Myelitis. Journal of Rheumatology, 2011, 38, 1520-1520.	1.0	5
157	Optimizing rituximab therapy for neuromyelitis optica. Nature Reviews Neurology, 2011, 7, 664-665.	4.9	10
158	Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Annals of Neurology, 2011, 69, 292-302.	2.8	8,001
159	Beneficial Plasma Exchange Response in Central Nervous System Inflammatory Demyelination. Archives of Neurology, 2011, 68, 870.	4.9	173
160	Failure of Autologous Hematopoietic Stem Cell Transplantation to Prevent Relapse of Neuromyelitis Optica. Archives of Neurology, 2011, 68, 953.	4.9	35
161	Association of IL2RA polymorphisms with susceptibility to multiple sclerosis is not explained by missense mutations in IL2RA. Multiple Sclerosis Journal, 2011, 17, 634-636.	1.4	8
162	Does detection of anti-AQP4 antibodies trump clinical criteria for neuromyelitis optica?. Neurology, 2011, 77, 812-813.	1.5	5

#	Article	IF	Citations
163	Do old HLA and mitochondrial DNA variants associate with demyelination types in young patients?. Neurology, 2011, 76, 768-769.	1.5	0
164	Intractable vomiting as the initial presentation of neuromyelitis optica. Annals of Neurology, 2010, 68, 757-761.	2.8	168
165	Neuromyelitis Optica. Blue Books of Neurology, 2010, 35, 258-275.	0.1	4
166	Compressive Myelopathy Mimicking Transverse Myelitis. Neurologist, 2010, 16, 120-122.	0.4	32
167	HLA-DRB1*1501 tagging rs3135388 polymorphism is not associated with neuromyelitis optica. Multiple Sclerosis Journal, 2010, 16, 981-984.	1.4	19
168	Perivenous demyelination: association with clinically defined acute disseminated encephalomyelitis and comparison with pathologically confirmed multiple sclerosis. Brain, 2010, 133, 333-348.	3.7	164
169	Japanese optic-spinal MS. Neurology, 2010, 75, 1404-1405.	1.5	5
170	ASYMPTOMATIC SPINAL CORD INVOLVEMENT IN POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME. Neurology, 2010, 74, 1478-1479.	1.5	10
171	Approach to acute or subacute myelopathy. Neurology, 2010, 75, S2-8.	1.5	43
172	Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). Brain, 2010, 133, 2626-2634.	3.7	316
173	Treatment of Neuromyelitis Optica With Mycophenolate Mofetil. Archives of Neurology, 2009, 66, 1128-33.	4.9	283
174	Diagnosis of Neuromyelitis Spectrum Disorders. Archives of Neurology, 2009, 66, 1134-8.	4.9	87
175	Neuromyelitis Optica IgG Serostatus in Fulminant Central Nervous System Inflammatory Demyelinating Disease. Archives of Neurology, 2009, 66, 964-6.	4.9	29
176	Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle and Nerve, 2009, 39, 87-90.	1.0	123
177	Gait Apraxia in Multiple Sclerosis. Canadian Journal of Neurological Sciences, 2009, 36, 562-565.	0.3	10
178	Neuromyelitis optica. Current Treatment Options in Neurology, 2008, 10, 55-66.	0.7	129
179	Neuromyelitis Optica and Nonâ€“Organ-Specific Autoimmunity. Archives of Neurology, 2008, 65, 78-83.	4.9	497
180	Laquinimod, a new oral drug for multiple sclerosis. Lancet, The, 2008, 371, 2059-2060.	6.3	6

#	Article	IF	Citations
181	Treatment of Neuromyelitis Optica With Rituximab. Archives of Neurology, 2008, 65, 1443.	4.9	445
182	Acute Disseminated Encephalomyelitis: Current Understanding and Controversies. Seminars in Neurology, 2008, 28, 084-094.	0.5	143
183	Neuromyelitis Optica and Autoimmune Diseasesâ€"Reply. Archives of Neurology, 2008, 65, 992.	4.9	4
184	An Approach to the Diagnosis of Acute Transverse Myelitis. Seminars in Neurology, 2008, 28, 105-120.	0.5	210
185	Interferon Gamma Allelic Variants. Archives of Neurology, 2008, 65, 349-57.	4.9	33
186	Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain, 2007, 130, 1194-1205.	3.7	650
187	Occurrence of CNS demyelinating disease in patients with myasthenia gravis. Neurology, 2007, 68, 1326-1327.	1.5	21
188	More on Multiple Sclerosis and Neuromyelitis Opticaâ€"Reply. Archives of Neurology, 2007, 64, 1802.	4.9	5
189	Neuromyelitis Optica Is Distinct From Multiple Sclerosis. Archives of Neurology, 2007, 64, 899.	4.9	82
190	Neuromyelitis optica. Current Opinion in Neurology, 2007, 20, 255-260.	1.8	85
191	Neuromyelitis optica: Changing concepts. Journal of Neuroimmunology, 2007, 187, 126-138.	1.1	104
192	The spectrum of neuromyelitis optica. Lancet Neurology, The, 2007, 6, 805-815.	4.9	1,897
193	NMO-IgG: A Specific Biomarker for Neuromyelitis Optica. Disease Markers, 2006, 22, 197-206.	0.6	82
194	Multiple sclerosis, brain radiotherapy, and risk of neurotoxicity: The Mayo Clinic experience. International Journal of Radiation Oncology Biology Physics, 2006, 66, 1178-1186.	0.4	39
195	OSMS is NMO, but not MS: proven clinically and pathologically. Lancet Neurology, The, 2006, 5, 110-111.	4.9	71
196	Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Annals of Neurology, 2006, 59, 566-569.	2.8	548
197	Neuromyelitis Optica Brain Lesions Localized at Sites of High Aquaporin 4 Expression. Archives of Neurology, 2006, 63, 964.	4.9	643
198	Not Every Patient With Multiple Sclerosis Should Be Treated at Time of Diagnosis. Archives of Neurology, 2006, 63, 611.	4.9	54

#	Article	IF	Citations
199	Brain Abnormalities in Neuromyelitis Optica. Archives of Neurology, 2006, 63, 390.	4.9	637
200	Diagnostic criteria for multiple sclerosis: 2005 revisions to the â€œMcDonald Criteriaâ€. Annals of Neurology, 2005, 58, 840-846.	2.8	4,495
201	Neuromyelitis optica. Current Treatment Options in Neurology, 2005, 7, 173-182.	0.7	90
202	Western vs optic-spinal MS: Two diseases, one treatment?. Neurology, 2005, 64, 594-595.	1.5	14
203	Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet, The, 2005, 366, 579-582.	6.3	411
204	Natural history of multiple sclerosis. Neurologic Clinics, 2005, 23, 17-38.	0.8	108
205	The Natural History of Recurrent Optic Neuritis. Archives of Neurology, 2004, 61, 1401.	4.9	100
206	Interferon beta-1b in secondary progressive MS. Neurology, 2004, 63, 1788-1795.	1.5	413
207	Clinical implications of benign multiple sclerosis: A 20-year population-based follow-up study. Annals of Neurology, 2004, 56, 303-306.	2.8	197
208	A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet, The, 2004, 364, 2106-2112.	6.3	2,839
209	Neuromyelitis optica: what it is and what it might be. Lancet, The, 2003, 361, 889-890.	6.3	82
210	Letter to the editor. Clinical Therapeutics, 2003, 25, 1888-1890.	1.1	1
211	Neuromyelitis optica. Neurology, 2003, 60, 848-853.	1.5	308
212	Cerebrospinal Fluid Oligoclonal Bands in the Diagnosis of Multiple Sclerosis. American Journal of Clinical Pathology, 2003, 120, 672-675.	0.4	59
213	A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain, 2002, 125, 1450-1461.	3.7	1,078
214	Plasma exchange for severe attacks of inflammatory demyelinating diseases of the central nervous system. Journal of Clinical Apheresis, 2001, 16, 39-42.	0.7	44
215	A point mutation in PTPRC is associated with the development of multiple sclerosis. Nature Genetics, 2000, 26, 495-499.	9.4	197
216	Multiple Sclerosis. New England Journal of Medicine, 2000, 343, 938-952.	13.9	3,121

#	Article	IF	Citations
217	A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Annals of Neurology, 1999, 46, 878-886.	2.8	832
218	Therapeutic plasma exchange for acute inflammatory demyelinating syndromes of the central nervous system. , 1999, 14, 144-148.		39
219	Therapeutic plasma exchange for acute inflammatory demyelinating syndromes of the central nervous system. , 1999, 14, 144.		1
220	A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. , 1999, 46, 878.		2
221	Familial chordoma with probable autosomal dominant inheritance. , 1998, 75, 335-336.		37
222	The Natural History of Multiple Sclerosis: Update 1998. Seminars in Neurology, 1998, 18, 301-307.	0.5	84
223	ACUTE LEUKOENCEPHALOPATHIES. Neurologist, 1998, 4, 148-166.	0.4	20
224	Screening for Major Depression in the Early Stages of Multiple Sclerosis. Canadian Journal of Neurological Sciences, 1995, 22, 228-231.	0.3	79
225	Meta-analysis of clinical studies of the efficacy of plasma exchange in the treatment of chronic progressive multiple sclerosis. Journal of Clinical Apheresis, 1995, 10, 163-170.	0.7	36
226	Natural history of multiple sclerosis. Annals of Neurology, 1994, 36, S6-S11.	2.8	323